Peninsula doripenem starts Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Peninsula's intravenous carbapenem antibiotic doripenem enters Phase III studies for complicated intra-abdominal infections, the firm says March 30. Per FDA guidelines, the primary endpoint will be response at test of cure visit...